Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Other

Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression

By The Northwire Desk — AI Analysis Feb 19, 2026 · 02:01 OPTI · 0.375 Optimi Health Corp.
OPTI · Price

Executive Summary

  • Optimi Health Corp. announced the export of its GMP‑manufactured 5 mg natural psilocybin capsules to Australia under the Authorised Prescriber Scheme, marking the company’s second finished psychedelic product supplied to that program.
  • The shipment expands Optimi’s portfolio in Australia, which already includes 40 mg and 60 mg MDMA capsules for PTSD treatment, and supports patients with treatment‑resistant depression (TRD).
  • The export is conducted under a Health Canada Drug Establishment Licence, with treatment outcomes to be tracked via Australia’s national patient registry in partnership with the Australian National University.

Key Details

  • Product: 5 mg natural psilocybin capsules (pharmaceutical‑grade, GMP‑manufactured).
  • Destination: Australia – Authorised Prescriber Scheme for treatment‑resistant depression (TRD).
  • Significance: Second finished drug product supplied to the Australian scheme; first psilocybin dosage form for TRD in that market.
  • Existing Australian Products: 40 mg and 60 mg MDMA capsules for post‑traumatic stress disorder (PTSD).
  • Regulatory Framework: Export authorized under Health Canada Drug Establishment Licence; product to be prescribed within Australia’s regulated framework.
  • Reimbursement: Department of Veterans’ Affairs may fully reimburse eligible patients for the therapy, covering both medication and psychotherapy.
  • Outcome Tracking: Clinical outcomes will be captured in Australia’s national patient registry through a partnership with Australian National University (ANU).
  • Contact for Access Inquiries (Australia): Mind Medicine Australia – [email protected].
  • Global Sales Contact: [email protected].

Notable Quotes

“Supplying pharmaceutical‑grade psilocybin outside of traditional clinical trials within a nationally regulated framework is an important milestone for our team and shareholders.” – Dane Stevens, CEO & Co‑Founder, Optimi Health Corp.

Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory